What is Idiopathic Pulmonary Fibrosis (IPF)? IPF is a chronic, progressive, lung disease characterized by disabling shortness of breath, declining exercise capacity and extensive formation of scar ...

What is Idiopathic Pulmonary Fibrosis (IPF)? IPF is a chronic, progressive, lung disease characterized by disabling shortness of breath, declining exercise capacity and extensive formation of scar ...

Traveling when you have idiopathic pulmonary fibrosis takes planning, but it’s doable. Experts share tips to help you stay ...

Dr Nathan discusses the trajectory of IPF management. How do you envision these investigational agents potentially being implemented into future treatment paradigms for idiopathic pulmonary fibrosis ...

Early diagnosis and treatment in IPF and PPF are vital, as fibrosis is irreversible and current therapies only slow progression. Current IPF treatments, pirfenidone and nintedanib, have significant ...

Please provide your email address to receive an email when new articles are posted on . Rentosertib was shown to be safe in a 12-week phase 2a trial in China. Two doses improved FVC vs. placebo.

Novel targets aim to stop lung scarring—where current drugs only slow it—while improving tolerability and unlocking fibrosis ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Swigris: Before we ...

The use of corticosteroids is linked to a higher risk for mortality in patients with acute exacerbations of idiopathic ...

BECHTELSVILLE, Pennsylvania (WPVI) -- Most of us take breathing for granted. But with pulmonary fibrosis, patients lose that despite the best medical efforts. That outcome is on the verge of change.